Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Goreisan Prospective Randomized Evaluation Study in Chronic Kidney Disease (GENERAL Study)
jRCTs051230192Active, not recruiting
- Sponsor
- Tsumura & Co.
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of oreongsan in chronic kidney disease (CKD) (2 arms), sponsored by Tsumura & Co. Primary endpoint: Rate of change in urinary protein-to-creatinine ratio at 24 weeks. Started May 2024; status: active, not recruiting.
02
Drugs
oreongsan
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCTs051230192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051230192.